New Zealand to fund Norgine's Xifaxan for hepatic encephalopathy

15 July 2014

New Zealand Pharmaceutical Management Agency PHARMAC has awarded a tender to Netherlands-headquartered Norgine for sole subsidized supply status and hospital supply status for rifaximin (Xifaxan) that was included in the 2013/2014 Invitation to Tender, dated November 7, 2013.

In summary, the effect of the decision is that:

rifaximin will be funded for the treatment of hepatic encephalopathy from August 1, 2014; and funding will be subject to Special Authority criteria in the community and restrictions in DHB hospitals.

Xifaxan tablets will be listed in Section B, and in the Hospital Medicines List (HML, Part II of Section H), of the Pharmaceutical Schedule from August 1, 2014 at a price and subsidy of NZ$625.00 ($550.18) per 56 tablets (ex-manufacturer, excluding GST).

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK